PATH | VRL
Menu

Prevention of Group B Streptococcal Disease in the First 3 Months of Life: Would Routine Maternal Immunization During Pregnancy Be Cost-Effective?

This article, published in Vaccine, reports the results of a study that evaluated the potential cost-effectiveness of a trivalent group B streptococcal (GBS) vaccine candidate with a decision-analytic model. The authors found that the addition of a trivalent GBS maternal vaccine to screening and intrapartum antibiotic prophylaxis might further reduce the burden of GBS disease among infants in the United States and may be comparable in cost-effectiveness to other vaccines recently approved for use in children and adolescents. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)

Author: Oster G, Edelsberg J, Hennegan K, et al.

Published: 2014

» Visit web page (English)

(Located at www.sciencedirect.com)

Citation: Oster G, Edelsberg J, Hennegan K, et al. Prevention of Group B Streptococcal Disease in the First 3 Months of Life: Would Routine Maternal Immunization During Pregnancy Be Cost-Effective? Vaccine. 2014;32(37):4778-4785. 

Resource types: Peer-reviewed journal

Diseases/vaccines: Group B Streptococcus (GBS)

Topics: Immunization financing, Disease burden and surveillance, Disease/vaccine specific information

Regions: North America and Europe